Thr25
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr25  -  RPT3 (human)

Site Information
LSVsRPQtGLsFLGP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3190483

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 4 ) , mass spectrometry ( 3 , 5 , 6 , 7 , 8 ) , mass spectrometry (in vitro) ( 4 ) , mutation of modification site ( 1 , 4 ) , phospho-antibody ( 1 , 2 , 4 ) , western blotting ( 1 , 2 , 4 )
Disease tissue studied:
breast cancer ( 1 , 4 ) , breast adenocarcinoma ( 1 , 4 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 1 , 3 , 4 ) , multiple myeloma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
DYRK2 (human) ( 1 , 4 )
Kinases, in vitro:
DYRK2 (human) ( 4 )
Treatments:
calyculin_A ( 4 ) , curcumin ( 2 ) , high_cell_density ( 4 ) , nocodazole ( 4 ) , serum_starvation ( 4 )

Downstream Regulation
Effects of modification on RPT3:
activity, induced ( 4 ) , enzymatic activity, induced ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 4 ) , carcinogenesis, inhibited ( 1 ) , cell cycle regulation ( 4 ) , cell growth, induced ( 4 )

References 

1

Banerjee S, et al. (2019) Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression. Proc Natl Acad Sci U S A 116, 24881-24891
31754034   Curated Info

2

Banerjee S, et al. (2018) Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proc Natl Acad Sci U S A 115, 8155-8160
29987021   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Guo X, et al. (2016) Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat Cell Biol 18, 202-12
26655835   Curated Info

5

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

6

Possemato A (2010) CST Curation Set: 9249; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

7

Possemato A (2009) CST Curation Set: 7303; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

8

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info